ClinicalTrials.gg
CompletedNCT01519921Updated Apr 21, 2016Results posted

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 7 sites in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-04-21.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
23rd of 59
150 · median 114
Started
2005
with 4 others
Phase 4
29 of 59
none open now
Registered
28th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 23rd largest by enrollment, is one of 5 that started in 2005, is one of 29 in phase 4, and was the 28th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B. Patients will be stratified into group A (treatment naïve patients) or B (YMDD mutant patients). All patients will receive PEGASYS 180 micrograms subcutaneously once weekly for 48 weeks, followed by 24 weeks of treatment-free follow up.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18-65 years of age
  • +ve for more than 6 months, HBeAg +ve, AntiHBs -ve
  • Detectable hepatitis B virus (HBV) DNA (>100,000 copies/mL)

Exclusion criteria

Exclusion Criteria:

  • Coinfection with hepatitis A, or (HIV)
  • Evidence of decompensated liver disease
  • A medical condition associated with chronic liver disease other than viral hepatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    PEG-IFN alfa-2a (Treatment naïve)

    Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.

    Drug: peginterferon alfa-2a [Pegasys]

  • Experimental
    PEG-IFN alfa-2a (YMDD mutant)

    Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.

    Drug: peginterferon alfa-2a [Pegasys]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72

    Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (EOF) period (24 weeks after the end of treatment) were classified as responders.

    Time frame: Week 72

  2. Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72

    Participants with loss of hepatitis B virus e antigen (HBeAg) at the EOF period (24 weeks after the end of treatment) were classified as responders.

    Time frame: Week 72

Secondary outcomes

  1. Percentage of Participants With ALT Normalization At Week 48 and Week 72

    Participants with ALT less than the upper limit of normal (ULN) at end of treatment (EOT) and EOF period were responders.

    Time frame: Week 48 and Week 72

  2. Percentage of Participants With Hepatitis B Virus DNA Below the Limit of Detection At Week 48 and Week 72

    Participants with HBV-DNA below the limit of detection i.e. \<174 copies/mL at EOT and EOF period were responders.

    Time frame: Week 48 and Week 72

  3. Percentage of Participants With a Combined Response At Week 48 and Week 72

    A responder with Combined Response was a participant with HBV-DNA\<100,000 copies/mL, HBeAg seroconversion (i.e. loss of HBeAg and presence of anti-HBe) and ALT normalization at EOT and EOF period.

    Time frame: Week 48 and Week 72

  4. Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion

    A responder was a participant with loss of HBeAg and presence of anti-HBe at EOT and EOF period.

    Time frame: Week 48 and Week 72

  5. Percentage of Participants With Loss of Hepatitis B Surface Antigen At Week 48 and Week 72

    A responder was a participant who were analysed with loss of Hepatitis B Surface Antigen (HBsAg) at EOT and EOF period.

    Time frame: Week 48 and Week 72

  6. Percentage of Participants With Hepatitis B Surface Antigen Seroconversion At Week 48 and Week 72

    A responder was a participant with loss of HBsAg and presence of anti-HBs at EOT and EOF period.

    Time frame: Week 48 and Week 72

  7. Number of Participants With Any Adverse Events and Any Serious Adverse Events

    An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Events (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Participants with any AEs and any SAEs have been presented.

    Time frame: Up to Week 72

07

Results

Posted Jan 25, 2016

Participant flow

A total of 150 participants were enrolled in this study conducted from 26 October 2005 to 24 June 2008 at 7 centers in Republic of Korea.

Participant flow — Overall Study
MilestonePEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Started8664
Completed6549
Not completed2115
Withdrew: Adverse event109
Withdrew: Lack of efficacy43
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up21
Withdrew: Treatment refusal21
Withdrew: High alanine aminotransferase (alt)01

Outcome measures

PrimaryPercentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72

Participants who had Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) levels below 100,000 copies per milliliter (mL) at the end of follow-up (EOF) period (24 weeks after the end of treatment) were classified as responders.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72
percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 7220.9 (12.9 to 31.0)21.9 (12.5 to 34.0)
PrimaryPercentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72

Participants with loss of hepatitis B virus e antigen (HBeAg) at the EOF period (24 weeks after the end of treatment) were classified as responders.

Time frame:
Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 72
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Percentage of Participants With Hepatitis B Virus e Antigen Loss At Week 7220.9 (12.9 to 31.0)23.4 (13.8 to 35.7)
SecondaryPercentage of Participants With ALT Normalization At Week 48 and Week 72

Participants with ALT less than the upper limit of normal (ULN) at end of treatment (EOT) and EOF period were responders.

Time frame:
Week 48 and Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With ALT Normalization At Week 48 and Week 72
percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)34.9 (24.9 to 45.9)29.7 (18.9 to 42.4)
Week 72 (EOF)36.0 (26.0 to 47.1)29.7 (18.9 to 42.4)
SecondaryPercentage of Participants With Hepatitis B Virus DNA Below the Limit of Detection At Week 48 and Week 72

Participants with HBV-DNA below the limit of detection i.e. \<174 copies/mL at EOT and EOF period were responders.

Time frame:
Week 48 and Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus DNA Below the Limit of Detection At Week 48 and Week 72
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)10.5 (4.9 to 18.9)10.9 (4.5 to 21.2)
Week 72 (EOF)3.5 (0.7 to 9.9)9.4 (3.5 to 19.3)
SecondaryPercentage of Participants With a Combined Response At Week 48 and Week 72

A responder with Combined Response was a participant with HBV-DNA\<100,000 copies/mL, HBeAg seroconversion (i.e. loss of HBeAg and presence of anti-HBe) and ALT normalization at EOT and EOF period.

Time frame:
Week 48 and Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With a Combined Response At Week 48 and Week 72
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)8.1 (3.3 to 16.1)9.4 (3.5 to 19.3)
Week 72 (EOF)9.3 (4.1 to 17.5)14.1 (6.6 to 25.0)
SecondaryPercentage of Participants With Hepatitis B Virus e Antigen Seroconversion

A responder was a participant with loss of HBeAg and presence of anti-HBe at EOT and EOF period.

Time frame:
Week 48 and Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)15.1 (8.3 to 24.5)23.4 (13.8 to 35.7)
Week 72 (EOF)20.9 (12.9 to 31.0)21.9 (12.5 to 34.0)
SecondaryPercentage of Participants With Loss of Hepatitis B Surface Antigen At Week 48 and Week 72

A responder was a participant who were analysed with loss of Hepatitis B Surface Antigen (HBsAg) at EOT and EOF period.

Time frame:
Week 48 and Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Loss of Hepatitis B Surface Antigen At Week 48 and Week 72
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)1.2 (0.03 to 6.3)1.6 (0.04 to 8.4)
Week 72 (EOF)1.2 (0.03 to 6.3)1.6 (0.04 to 8.4)
SecondaryPercentage of Participants With Hepatitis B Surface Antigen Seroconversion At Week 48 and Week 72

A responder was a participant with loss of HBsAg and presence of anti-HBs at EOT and EOF period.

Time frame:
Week 48 and Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Hepatitis B Surface Antigen Seroconversion At Week 48 and Week 72
Percentage of participantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Week 48 (EOT)1.2 (0.03 to 6.3)0.0 (0.0 to 0.0)
Week 72 (EOF)1.2 (0.03 to 6.3)1.6 (0.04 to 8.4)
SecondaryNumber of Participants With Any Adverse Events and Any Serious Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A Serious Adverse Events (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Participants with any AEs and any SAEs have been presented.

Time frame:
Up to Week 72
Reported as:
Number · Participants
Number of Participants With Any Adverse Events and Any Serious Adverse Events
ParticipantsPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Any AEs7554
Any SAEs45

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN Alfa-2a (Treatment naïve)—4/86 (4.7%)69/86 (80.2%)
PEG-IFN Alfa-2a (YMDD Mutant)—5/64 (7.8%)52/64 (81.3%)
Most frequent serious events
Most frequent serious events
EventPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
Liver function test abnormalInvestigations0/862/64
Abdominal pain upperGastrointestinal disorders0/861/64
AppendicitisGastrointestinal disorders0/861/64
PyrexiaGeneral disorders1/861/64
Cholecystitis acuteHepatobiliary disorders0/861/64
Wrist fractureInjury, poisoning and procedural complications0/861/64
LymphadenopathyBlood and lymphatic system disorders1/860/64
ExomphalosGastrointestinal disorders1/860/64
HaemorrhoidsGastrointestinal disorders1/860/64
BronchopneumoniaRespiratory, thoracic and mediastinal disorders1/860/64
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)
AlopeciaSkin and subcutaneous tissue disorders34/8624/64
NeutropeniaBlood and lymphatic system disorders21/8618/64
FatigueGeneral disorders16/8617/64
HeadacheNervous system disorders16/8615/64
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders10/8613/64
Influenza like illnessGeneral disorders11/8612/64
PruritusSkin and subcutaneous tissue disorders11/8612/64
PainGeneral disorders13/866/64
DyspepsiaGastrointestinal disorders10/861/64
Liver function test abnormalInvestigations10/867/64

Baseline characteristics

Baseline characteristics were analysed on Intent-to-treat (ITT) population which included all participants who received at least one dose of study drug. The ITT and the safety populations were identical.

Age, Continuous
Age, Continuous(Years)PEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)Total
Mean35.3 ± 9.2036.8 ± 9.035.9 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN Alfa-2a (Treatment naïve)PEG-IFN Alfa-2a (YMDD Mutant)Total
Female231033
Male6354117
08

Study locations

7 sites
  • Busan, 49241, Korea, Republic of
  • Daegu, 41944, Korea, Republic of
  • Seoul, 03722, Korea, Republic of
  • Seoul, 05505, Korea, Republic of
  • Seoul, 06351, Korea, Republic of
  • Seoul, 08308, Korea, Republic of
  • Seoul, 14647, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2012
First posted
Jan 27, 2012
Start
Oct 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jan 25, 2016
Last update
Apr 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01519921
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2012
Start date
Oct 2005
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jan 25, 2016
Last update
Apr 21, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion